VANISH
2016 SepsisVasopressin vs Nad for initial vasopressor on rate of renal failure, and the interaction of corticosteroids in patients with septic shock.
Clinical Question
Does early vasopressin use reduce the risk of kidney failure in patients
with septic shock compared with norepinephrine?
Critical Appraisal
Key findings
Less RRT in vasopressin group but no difference in number of renal failure free days in all four groups. Low use of steroids.
Strengths
Clinical staff blinded , Researchers blinded
Critique
Only 35% received steroid. Timing of RRT was not controlled.
- Population
- Sepsis
- Population Details
- Not recorded
- Intervention Arms
-
Vasopressin (up to 0.06 U/min) + (Hydrocortisone or Placebo)
Vasopressin (up to 0.06 U/min) + (Hydrocortisone or Placebo) - Control Arms
-
Norepinephrine + (Hydrocortisone or Placebo)
- Primary Outcome
- Rate of AKI
- Secondary Outcomes
- Less RRT in vasopressin group , No difference in number of days alive and free of kidney failure , No difference in serious adverse events
- P Value
- 0.5
Outcome Results
Not recorded
Primary location: UK
Landmark trial